Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2023 · 10-Q
Revenue$0.00$0.00no prior Q2 2022 on file Net Income-$33.55M-$33.55MN/M vs Q2 2022 EPS Diluted-$68.43-$68.43N/M vs Q2 2022 Operating Income-$10,573,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,589,000N/M ended Dec 31, 2022 · filed Feb 14, 2023 · 45 d after period end